- Cardamomin
-
-
2026-08-25
- CAS:18956-16-6
- Min. Order: 1KG
- Purity: 0.99
- Supply Ability: 1000KG
- Cardamonin
-
- $38.00
-
2026-07-27
- CAS:18956-16-6
- Purity: 99.78%
- Supply Ability: 10g
- CARDAMONIN
-
-
2025-06-27
- CAS:18956-16-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500000kg
|
| | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one Basic information |
| Product Name: | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one | | Synonyms: | (E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-;1-(2,4-Dihydroxy-6-methoxyphenyl);-3-phenylprop-2-en-1-one;1-(2,4-Dihydroxy-6-Methoxyphenyl)-3-phenylprop-2-en-1-one;2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-;Natural Alpinia Seed Extract 98% Cardamonin Powder CAS?18956-16-6;ARDAMONIN;(E)-1-(2,4-DIHYDROXY-6-METHOXY-PHENYL)-3-PHENYL-PROPENONE | | CAS: | 18956-16-6 | | MF: | C16H14O4 | | MW: | 270.28 | | EINECS: | | | Product Categories: | | | Mol File: | 18956-16-6.mol |  |
| | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one Chemical Properties |
| Melting point | 178 °C | | Boiling point | 484.5±45.0 °C(Predicted) | | density | 1.282±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: 125 mg/mL (462.48 mM) | | form | Solid | | pka | 7.00±0.40(Predicted) | | color | Light yellow to yellow |
| | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one Usage And Synthesis |
| Uses | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one is inhibits NO and PGE2 production and inhibits TXB2 production. | | Definition | ChEBI: Cardamonin is a member of chalcones. | | in vivo | Cardamonin (oral gavage; 20, 40 or 80 mg/kg; once) treatments alleviates doxorubicin-induced cardiotoxicity and inhibits apoptosis in doxorubicin-challenged mice[4]. | Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] | | Dosage: | 20, 40 or 80 mg/kg | | Administration: | Oral gavage; 20, 40 or 80 mg/kg; once | | Result: | Rescued the reduction of LVEF% and LVFS% by doxorubicin, reduced the increasement of serum LDH, CK-MB and Tn-T levels by doxorubicin in a dose-dependent manner, improved doxorubicin-induced histological changes, and attenuated collagen accumulation in cardiac sections by doxorubicin in a dose-dependent manner. |
| Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] | | Dosage: | 20, 40 or 80 mg/kg | | Administration: | Oral gavage; 20, 40 or 80 mg/kg; once | | Result: | Rescued Bcl-2, and inhibited Bax and Caspase-3 cleavage in heart tissues from doxorubicin-challenged mice. |
|
| | 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one Preparation Products And Raw materials |
|